Roth Remains Neutral on Peregrine Pharma (PPHM); Pipeline Advancing Well, but Catalysts Remain
Tweet Send to a Friend
Roth Capital affirms Peregrine Pharma (Nasdaq: PPHM) with a Neutral rating and $0.50 price target following Q1 results issued Thursday ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
